OBJECTIVES: To assess willingness to participate in HIV vaccine trials and possible barriers to participation. METHODS: Questionnaire survey of participants completing a 2-year community-based HIV Vaccine Preparedness Study, followed by cross sectional analysis of data. RESULTS: 95% of participants were willing to participate in a trial with similar attributes to the Vaccine Preparedness Study. Certain hypothetical trial attributes significantly reduced willingness to participate: The requirement to delay pregnancy (for females) had the largest effect, reducing willingness to participate from 97% to 23% (P < 0.0001). Larger blood draws had the second largest effect: 95-55% (P < 0.0001). The possibility of receiving either candidate vaccine or placebo had the third largest effect: 95-73% (P < 0.0001). Monthly study visits had the fourth largest effect: 95-92% (P < 0.0001). Trial duration longer than 2 years had the least effect: 95-93% (P = 0.0025). Combined attributes reduced willingness to participate from 95% to 43% (McNemar's chi(2) = 521.00; P < 0.0001) overall and 97-11% (McNemar's chi(2) = 531.00; P < 0.0001) for female participants. Physical harm concerns (adjusted OR = 34.9; 95% CI, 10.4-118) and a low risk behaviour index (adjusted OR = 0.09; 95% CI, 0.01-0.73) were associated with unwillingness to participate. CONCLUSIONS: We found a high level of willingness to participate in HIV vaccine trials in this population. However, certain HIV vaccine trial requirements were associated with reduced willingness to participate. Community as well as individual concerns will have to be carefully addressed in planned HIV vaccine trials.
OBJECTIVES: To assess willingness to participate in HIV vaccine trials and possible barriers to participation. METHODS: Questionnaire survey of participants completing a 2-year community-based HIV Vaccine Preparedness Study, followed by cross sectional analysis of data. RESULTS: 95% of participants were willing to participate in a trial with similar attributes to the Vaccine Preparedness Study. Certain hypothetical trial attributes significantly reduced willingness to participate: The requirement to delay pregnancy (for females) had the largest effect, reducing willingness to participate from 97% to 23% (P < 0.0001). Larger blood draws had the second largest effect: 95-55% (P < 0.0001). The possibility of receiving either candidate vaccine or placebo had the third largest effect: 95-73% (P < 0.0001). Monthly study visits had the fourth largest effect: 95-92% (P < 0.0001). Trial duration longer than 2 years had the least effect: 95-93% (P = 0.0025). Combined attributes reduced willingness to participate from 95% to 43% (McNemar's chi(2) = 521.00; P < 0.0001) overall and 97-11% (McNemar's chi(2) = 531.00; P < 0.0001) for female participants. Physical harm concerns (adjusted OR = 34.9; 95% CI, 10.4-118) and a low risk behaviour index (adjusted OR = 0.09; 95% CI, 0.01-0.73) were associated with unwillingness to participate. CONCLUSIONS: We found a high level of willingness to participate in HIV vaccine trials in this population. However, certain HIV vaccine trial requirements were associated with reduced willingness to participate. Community as well as individual concerns will have to be carefully addressed in planned HIV vaccine trials.
Authors: Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Joachim Mwami; Muhammad Bakari; Eric Sandström; Asli Kulane Journal: BMC Public Health Date: 2010-05-28 Impact factor: 3.295
Authors: Erin M Kahle; Angela Kashuba; Jared M Baeten; Kenneth H Fife; Connie Celum; Andrew Mujugira; Max Essex; Guy De Bruyn; Anna Wald; Deborah Donnell; Grace John-Stewart; Sinead Delany-Moretlwe; Nelly R Mugo; Carey Farquhar; Jairam R Lingappa Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Rebecca Giguere; Gregory D Zimet; Jessica A Kahn; Curtis Dolezal; Cheng-Shiun Leu; Marina Mabragaña; Ian McGowan; Alex Carballo-Diéguez Journal: World J AIDS Date: 2013-09
Authors: Barbara S Mensch; Barbara A Friedland; Sharon A Abbott; Lauren L Katzen; Waimar Tun; Christine A Kelly; Avina Sarna; Aylur K Srikrishnan; Suniti Solomon Journal: AIDS Behav Date: 2013-02
Authors: Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Muhammad Bakari; Fred Mhalu; Asli Kulane Journal: PLoS One Date: 2011-02-16 Impact factor: 3.240